|
Thursday 8th September 2022 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has received clarification during recent discussions with the Medicinal Cannabis Agency related to technical aspects associated with achieving the New Zealand Minimum Quality Standard for cannabis flower as a finished product. The insights gained have helped Cannasouth optimise post-harvest processes which will ultimately lead to a higher quality finished product.
The adopted process improvements remove complexity and streamline our operations, however require additional data to validate the changes. This data will be gathered during our upcoming commercial harvest scheduled to commence on the 19th of September.
Validation is a key component of the Good Manufacturing Practices (GMP) accreditation process. Cannasouth has sought deferral of its GMP audit while the new data pack is assembled. Cannasouth is working with the regulators to arrange a new audit date at the earliest opportunity.
GMP covers the post-harvest, drying and packing processes and is required for higher value premium flower to be used as a finished product in most jurisdictions, including New Zealand. This is an important distinction from Good Agricultural Collection Practices (GACP) accreditation, which Cannasouth achieved in August 2022, which opens the pathway for the export of cannabis flower as a start material for further manufacture.
-ENDS-
NXZ MAP_CBD Regulatory Clarification and GMP Audit Timing
No comments yet
PYS - PaySauce to announce F26 full year results on 27 May 2026
PEB - Draft LCD Proposes Medicare Coverage for Triage and Triage
MEL - Meridian Energy monthly operating report for April 2026
FBU - Sale of South Australian property
AIR - Air New Zealand market update
May 14th Morning Report
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million